Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments
- S. Tesfaye, A. Boulton, P. Valensi
- MedicineDiabetes Care
- 1 October 2010
Preceding the joint meeting of the 19th annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (NEURODIAB) and the 8th International Symposium on Diabetic…
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- D. Adams, A. González-Duarte, O. Suhr
- MedicineNew England Journal of Medicine
- 5 July 2018
Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry
- P. Dyck, W. Sherman, C. Swanson
- MedicineAnnals of Neurology
- 1 December 1980
A comparison of scored symptoms and signs and clinical neurophysiological studies against morphometric and teased fiber studies of sural nerve demonstrated that the former three provide sensitive and reliable measures of severity of neuropathy that can be used for controlled clinical trials of diabetic neuropathy.
Quantitative sudomotor axon reflex test in normal and neuropathic subjects
Postganglionic sweat output in human subjects resulting from axon reflex stimulation using acetylcholine electrophoresis is quantified using an acrylic plastic chamber placed over a defined area of skin.
Chronic inflammatory polyradiculoneuropathy.
- P. Dyck, A. Lais, M. Ohta, J. A. Bastron, H. Okazaki, R. Groover
- Medicine, BiologyMayo Clinic proceedings
- 1 November 1975
The diagnostic criteria, natural history, nerve conduction characteristics, pathology, laboratory features, and efficacy of corticosteroid treatment have been evaluated personally in 53 patients with…
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort
Two thirds of diabetic patients have objective evidence for some variety of neuropathy, but only about 20% have symptoms, and only 6% of IDDM and only 1% of NIDDM patients have sufficiently severe polyneuropathy to be graded stage 2b, and none were graded stage 3.
Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss
- C. Klein, M. Botuyan, P. Dyck
- BiologyNature Genetics
- 14 April 2011
These mutations cause premature degradation of mutant proteins, reduced methyltransferase activity and impaired heterochromatin binding during the G2 cell cycle phase leading to global hypomethylation and site-specific hypermethylation.
Detection, characterization, and staging of polyneuropathy: Assessed in diabetics
- P. Dyck
- Medicine, PsychologyMuscle and Nerve
- 1 January 1988
Staging approaches to staging severity of neuropathy should be developed and used in expressing abnormality and minimal criteria for the diagnosis of diabetic polyneuropathy have been proposed and validated tests to assess neuropathic symptoms and sensory deficits have been developed.
Natural history of brachial plexus neuropathy. Report on 99 patients.
- P. Tsairis, P. Dyck, D. W. Mulder
- Medicine, PsychologyArchives of Neurology
- 1 August 1972
These studies support the contention that this form of neuropathy is a clinical entity with, in most cases, a fairly typical pattern of symptoms and signs and the overall prognosis is excellent despite the severity and extent of the lesion.
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
- E. Mathey, Susanna B. Park, C. Lin
- Biology, MedicineJournal of Neurology Neurosurgery & Psychiatry
- 12 February 2015
In this review, the roles of the cellular and humoral immune systems in the pathogenesis of CIDP will be discussed and delineation of clinical phenotypes and the underlying disease mechanisms might help guide diagnostic and individualised treatment strategies for CIDs.
...
...